Cargando…

Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage

BACKGROUND: To examine whether metabotropic glutamate (mGlu) receptors have any role in mechanisms that shape neuronal vulnerability to ischemic damage, we used the 4-vessel occlusion (4-VO) model of transient global ischemia in rats. 4-VO in rats causes a selective death of pyramidal neurons in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Motolese, Marta, Mastroiacovo, Federica, Cannella, Milena, Bucci, Domenico, Gaglione, Anderson, Riozzi, Barbara, Lütjens, Robert, Poli, Sonia M., Celanire, Sylvain, Bruno, Valeria, Battaglia, Giuseppe, Nicoletti, Ferdinando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619332/
https://www.ncbi.nlm.nih.gov/pubmed/26496940
http://dx.doi.org/10.1186/s13041-015-0158-2
_version_ 1782397077919105024
author Motolese, Marta
Mastroiacovo, Federica
Cannella, Milena
Bucci, Domenico
Gaglione, Anderson
Riozzi, Barbara
Lütjens, Robert
Poli, Sonia M.
Celanire, Sylvain
Bruno, Valeria
Battaglia, Giuseppe
Nicoletti, Ferdinando
author_facet Motolese, Marta
Mastroiacovo, Federica
Cannella, Milena
Bucci, Domenico
Gaglione, Anderson
Riozzi, Barbara
Lütjens, Robert
Poli, Sonia M.
Celanire, Sylvain
Bruno, Valeria
Battaglia, Giuseppe
Nicoletti, Ferdinando
author_sort Motolese, Marta
collection PubMed
description BACKGROUND: To examine whether metabotropic glutamate (mGlu) receptors have any role in mechanisms that shape neuronal vulnerability to ischemic damage, we used the 4-vessel occlusion (4-VO) model of transient global ischemia in rats. 4-VO in rats causes a selective death of pyramidal neurons in the hippocampal CA1 region, leaving neurons of the CA3 region relatively spared. We wondered whether changes in the expression of individual mGlu receptor subtypes selectively occur in the vulnerable CA1 region during the development of ischemic damage, and whether post-ischemic treatment with drugs targeting the selected receptor(s) affords neuroprotection. RESULTS: We found that 4-VO caused significantly reduction in the transcript of mGlu2 receptors in the CA1 region at times that preceded the anatomical evidence of neuronal death. Down-regulation of mGlu2 receptors was associated with reduced H3 histone acetylation at the Grm2 promoter. The transcripts of other mGlu receptor subtypes were unchanged in the CA1 region of 4-VO rats. Ischemia did not cause changes in mGlu2 receptor mRNA levels in the resistant CA3 region, which, interestingly, were lower than in the CA1 region. Targeting the mGlu2 receptors with selective pharmacologic ligands had profound effects on ishemic neuronal damage. Post-ischemic oral treatment with the selective mGlu2 receptor NAM (negative allosteric modulator), ADX92639 (30 mg/kg), was highly protective against ischemic neuronal death. In contrast, s.c. administration of the mGlu2 receptor enhancer, LY487379 (30 mg/kg), amplified neuronal damage in the CA1 region and extended the damage to the CA3 region. CONCLUSION: These findings suggest that the mGlu2 receptor is an important player in mechanisms regulating neuronal vulnerability to ischemic damage, and that mGlu2 receptor NAMs are potential candidates in the experimental treatments of disorders characterized by brain hypoperfusion, such as hypovolemic shock and cardiac arrest.
format Online
Article
Text
id pubmed-4619332
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46193322015-10-26 Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage Motolese, Marta Mastroiacovo, Federica Cannella, Milena Bucci, Domenico Gaglione, Anderson Riozzi, Barbara Lütjens, Robert Poli, Sonia M. Celanire, Sylvain Bruno, Valeria Battaglia, Giuseppe Nicoletti, Ferdinando Mol Brain Research BACKGROUND: To examine whether metabotropic glutamate (mGlu) receptors have any role in mechanisms that shape neuronal vulnerability to ischemic damage, we used the 4-vessel occlusion (4-VO) model of transient global ischemia in rats. 4-VO in rats causes a selective death of pyramidal neurons in the hippocampal CA1 region, leaving neurons of the CA3 region relatively spared. We wondered whether changes in the expression of individual mGlu receptor subtypes selectively occur in the vulnerable CA1 region during the development of ischemic damage, and whether post-ischemic treatment with drugs targeting the selected receptor(s) affords neuroprotection. RESULTS: We found that 4-VO caused significantly reduction in the transcript of mGlu2 receptors in the CA1 region at times that preceded the anatomical evidence of neuronal death. Down-regulation of mGlu2 receptors was associated with reduced H3 histone acetylation at the Grm2 promoter. The transcripts of other mGlu receptor subtypes were unchanged in the CA1 region of 4-VO rats. Ischemia did not cause changes in mGlu2 receptor mRNA levels in the resistant CA3 region, which, interestingly, were lower than in the CA1 region. Targeting the mGlu2 receptors with selective pharmacologic ligands had profound effects on ishemic neuronal damage. Post-ischemic oral treatment with the selective mGlu2 receptor NAM (negative allosteric modulator), ADX92639 (30 mg/kg), was highly protective against ischemic neuronal death. In contrast, s.c. administration of the mGlu2 receptor enhancer, LY487379 (30 mg/kg), amplified neuronal damage in the CA1 region and extended the damage to the CA3 region. CONCLUSION: These findings suggest that the mGlu2 receptor is an important player in mechanisms regulating neuronal vulnerability to ischemic damage, and that mGlu2 receptor NAMs are potential candidates in the experimental treatments of disorders characterized by brain hypoperfusion, such as hypovolemic shock and cardiac arrest. BioMed Central 2015-10-24 /pmc/articles/PMC4619332/ /pubmed/26496940 http://dx.doi.org/10.1186/s13041-015-0158-2 Text en © Motolese et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Motolese, Marta
Mastroiacovo, Federica
Cannella, Milena
Bucci, Domenico
Gaglione, Anderson
Riozzi, Barbara
Lütjens, Robert
Poli, Sonia M.
Celanire, Sylvain
Bruno, Valeria
Battaglia, Giuseppe
Nicoletti, Ferdinando
Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage
title Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage
title_full Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage
title_fullStr Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage
title_full_unstemmed Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage
title_short Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage
title_sort targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619332/
https://www.ncbi.nlm.nih.gov/pubmed/26496940
http://dx.doi.org/10.1186/s13041-015-0158-2
work_keys_str_mv AT motolesemarta targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT mastroiacovofederica targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT cannellamilena targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT buccidomenico targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT gaglioneanderson targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT riozzibarbara targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT lutjensrobert targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT polisoniam targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT celaniresylvain targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT brunovaleria targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT battagliagiuseppe targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage
AT nicolettiferdinando targetingtype2metabotropicglutamatereceptorstoprotectvulnerablehippocampalneuronsagainstischemicdamage